Source: Heart Future; Editor: Sophia
Reprint Requirements: If the source of the article is indicated at the beginning of the text, it can be reprinted directly.
Recently，Medtronic (NYSE: MDT)Announcement will be made inUnited States, CanadaLaunch itsStreerant Aortic Guidewire，ConvenientDiagnosis or interventional aortic surgeryCatheter Placement and Replacement During the Period, GuidewireSupports Endovascular Aneurysm Repair (EVAR) and Thoracic Endovascular Aortic Repair (TEVAR) surgeries。
Streerant Aortic GuidewireGuidewire is one of the basic instruments in coronary intervention., used to access coronary arteries or navigate through tortuous, calcified, narrowed, collateral circulation to reach the target., establishing rail transport for balloons, stents, and microcatheters; used for guidewire escalation or de-escalation techniques to open coronary occlusive lesions; advance into coronary branches in advance to serve protective and landmark functions, etc.In 2022,GlobalThe Market for Coronary GuidewiresFor 5.12Billion US dollars,It is expected to reach 722.9 million US dollars by 2030, is expected to grow at a compound annual growth rate (CAGR) of 4.4% during 2022-2030.As the number of coronary heart disease patients in China continues to rise, with the upgrading of coronary intervention technology, more comprehensive coverage of national medical insurance, and the continuous improvement of grassroots medical standards,It is expected that the demand for future coronary intervention surgeries will continue to be released.In 2024, the total number of surgeries will reach 1.927 million.。From 2019 to 2024, the annual compound growth rate of coronary artery interventional procedures in China reached 12.1%.In 2024,Market Size in Coronary InterventionWill double to reachRMB 20 billionAbove。Coronary guidewires in China are mainly dependent on imports, with only a few domestically produced companies, such asApex Medical, Gachi Biotech, and Vascular Medicaletc.Only Epote Company launched the AnyreachC guidewire series for coronary interventional diagnosis and treatment in 2019.Large market development space。# Research and Development BackgroundThe aorta is the main conduit for transporting blood to all parts of the body. It originates from the left ventricle of the heart, arches upward and to the right, then curves downward slightly in an arc, and descends along the spine. In the thoracic and abdominal cavities, it branches into many smaller arteries.
Among all aortic diseases,The most fatal conditions are aortic aneurysms and aortic dissections.. The main surgical methods in clinical practice areOpen Repair SurgeryAndCavity Repair (EVAR/TEVAR)。
These two surgeries each have their own advantages and disadvantages.。Endovascular Aneurysm Repair (EVAR/TEVAR) has gained clinical favor due to its minimally invasive treatment approach and short-term benefits; however, its long-term outcomes are inferior to those of open repair.
# Streerant Aortic Guidewire
Steerant Aortic Guidewire has15 cmSoft, Non-Traumatic Tip, which can gradually transition to a solid main body,Provides protection for the fragile aortic anatomy。Guidewire Length for EVARCustomized to 200 cm, non-bent length of 260 cm;Dual Curvature Length for TEVARCustomized to 260 cm.Guidewire has a diameter of 0.89 millimeters and an 8-centimeter radiopaque spring., which can improve visibility.Medtronic also designedPolytetrafluoroethylene (PTFE) Coating, enabling smooth device delivery.Dr. Naiem Nassiri completed the procedure using the guidewire at Norwalk Hospital in Connecticut.The First EVAR Case Surgery;Doctor Patrick E. Muck completed the procedure using the guidewire at Good Samaritan Hospital in Ohio.The First TEVAR Case Surgery.According to Medtronic, both the EVAR and TEVAR procedures are minimally invasive surgeries used to treat abdominal aortic aneurysms and thoracic aortic aneurysms.Dr. Patrick E. Muck Steerant Aortic GuidewireCalled"The Pillar of Aortic Surgery"。General Manager of Medtronic Aortic BusinessDr. Simona ZannettiIndicates:
"We are excited to offer an innovative device for aortic procedures that strikes the right balance between stiffness and trackability while providing physicians with optimal length and control. We look forward to introducing the Steerant device to clinicians treating aneurysms in the United States and Canada."# Another related product ——Intra-aortic Anchoring System
Medtronic'sHeli-FX™ EndoAnchor System, applicable toFixation and Sealing Between Endovascular Aortic Stent Grafts and Autologous Arteries, SpecializedForDesigned to address the issues of endoleaks and stent graft migration in cavity repair procedures.Medtronic Presented Clinical Study Results of Heli-FX EndoAnchor at VEITH 2023, Showing:In selected patients,EndoAnchor Can Effectively Reduce the Incidence of Type Ia Endoleaks, promoting tumor cyst regression;In patients with wide aneurysm necks,The 3-year freedom rate from Type Ia endoleaks was 98.5%.。In addition, when the neck of a renal abdominal aortic aneurysm (AAA) is too short, endosuture aneurysm repair (ESAR) can be used.The ESAR procedure using the Heli-FX™ EndoAnchor System in conjunction with the Endurant Stent Graft System canSuitable for patients with aortic aneurysm neck length less than 10mm to 4mm, which also allows more patients to benefit from endovascular interventional therapy.But for now,Heli-FX EndoAnchor surgery is more difficult with a long learning curve.。Medtronic (Medtronic, NYSE: MDT) was founded in 1949, with its headquarters in Minneapolis, Minnesota, USA. It is a global leading medical technology company, employing over 95,000 people.
Medtronic's innovative solutions have expanded to more than 70 key disease areas, committing to provide lifelong treatment options for patients with chronic conditions. Every second, two patients worldwide benefit from Medtronic's medical technologies or therapies.Medtronic's main businesses includeCardiovascular, Medical Surgical, Neuroscience, and DiabetesFour business segments, includingCardiovascular accounts for the highest proportion。
Taking the 2023 financial report as an example, the company's total revenue was $31.227 billion, ranking first in revenue among global medical device companies. Among this, the cardiovascular business revenue was $11.573 billion, accounting for 37.06%, includingCardiac Rhythm and Heart Failure (CRHF), Structural Heart and Aorta (SHA), and Coronary and Peripheral Vascular (CPV)Three departments.
▲2023 Annual Report (Source: Company Official Website)
